Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action.
D000818:Animals; D000950:Antigens, Ly / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D007167:Immunotherapy; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D012208:Rhabdomyosarcoma / Q000276:immunology / Q000628:therapy*; D012513:Sarcoma, Experimental / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D018800:Thy-1 Antigens
D000950:Antigens, Ly; D000954:Antigens, Surface; D018800:Thy-1 Antigens; D003520:Cyclophosphamide